Results of ENCHANTED have been published.

CRISIS I is a prospective, multicenter, randomized controlled trial, to asses the impact of intensive blood pressure control on clinical outcome of acute ischemic stroke patients with successful recanalization after endovascular therapy.

CRISIS I aims to determine the effectiveness of more intensive BP lowering target (<120 mmHg) compared to standard BP management target (<140mmHg) on functional outcome in patients with successful recanalization post-MT for AIS due to anterior circulation large vessel occlusion (LVO).

Inclusion Criteria:

• Age ≥18 years
• Diagnosis of AIS with anterior circulation LVO confirmed by brain imaging
• To receive MT <24 hours after AIS onset according to local guidelines
• Successful recanalization (TICI score ≥2b) after MT
• Sustained systolic BP ≥140 mmHg (defined as 2 successive readings <10 mins) within 60 minutes after recanalization
• Provide written informed consent (or approved surrogate)
• Perform CTA or MRI before endovascular therapy
• Signed an approved informed consents

Exclusion Criteria:

• Significant pre-stroke disability (mRS scores 2-5)
• Definite indication/contraindication to different intensities of BP lowering treatment
• Specific contraindications to any of the BP agents to be used (eg, patients who are hypersensitive (allergic) to any of the ingredients)
• Unlikely to potentially benefit from therapy (e.g. advanced dementia) or very high likelihood of death within 24 hours post-MT, judged by responsible treating clinician
• Other medical illness that interferes with outcome assessments and follow-up (e.g.advance cancer and renal failure); Women who are lactating
• Other conditions inappropriate for inclusion judged by investigators

Open intervention; outcome assessments undertaken by trained research staff who are kept blind to treatment allocation